EUMAR TECHNOLOGY LIMITED

Company number 01884830 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

🏥 Financial Health Assessment: Eumar Technology Limited

"Annual Check-up for Companies House Registration 01884830"


📋 Patient Profile

Attribute Detail
Patient ID 01884830
Age 40 years (incorporated 1985)
Specialty Clean room technology, medical device manufacturing
Ward Whitestone Business Park, Hereford
Consultants Acre Accountancy Limited
Filing Status Unaudited abridged accounts, small companies regime

1️⃣ Financial Health Score: A- (Excellent)

"A mature, financially robust patient with a strong balance sheet and a hearty pulse of profitability — though a couple of vital signs deserve monitoring."

Score Justification: - ✅ Decades of operational longevity (40+ years) - ✅ Strong profit generation - ✅ Excellent solvency and liquidity - ✅ Improving net worth trajectory - ⚠️ Minor attention needed on cash trend and receivables - ⚠️ Recent director turnover


2️⃣ Key Vital Signs — Critical Metrics

🩺 Pulse & Blood Pressure (Liquidity Ratios)

Metric 2025 2024 Reading
Current Ratio 8.42 4.43 🟢 Exceptional — vastly exceeds healthy benchmark of 1.5–2.0
Quick Ratio (excl. stock) 7.03 3.28 🟢 Very strong
Cash Ratio 2.11 1.92 🟢 Bullish — could pay off all short-term debt twice over

Interpretation: The "circulatory system" is in superb shape. The company has £2.11 in cash for every £1 of short-term obligation.

❤️ Heart Function (Profitability)

Metric 2025 Note
Profit for Year £624,570 Robust — built from retained earnings movement
Dividends Paid £1,100 Conservative distribution, capital retained for reinvestment
Profit Margin Proxy (Net Assets growth) +18.8% Strong YoY equity growth

🦴 Bone Density (Solvency)

Metric 2025 Reading
Total Liabilities £323,446 🟢 Very low — £732K reduction since 2022
Debt-to-Equity 0.082 (8.2%) 🟢 Excellent — minimal leverage
Net Assets £3,941,269 🟢 Substantial, growing 18.8% YoY
Provisions for Liabilities £408,466 Likely deferred tax — a "healthy" liability

🩸 Blood Test (Working Capital & Asset Quality)

Metric 2025 2024 YoY Change
Net Current Assets £2,400,405 £1,693,119 +41.8% 🟢
Stock £452,042 £566,080 -20.1% 🟡 Watch
Debtors £1,590,048 £674,184 +135.9% 🔴 Investigate
Cash £681,761 £946,562 -28.0% 🔴 Notable
Tangible Fixed Assets £1,955,502 £2,050,005 Slight reduction after £303K additions

3️⃣ Diagnosis — What the Numbers Reveal

🟢 Positive Symptoms (Signs of Robust Health)

  1. "Strong heart" — Profitable Operations: The retained earnings grew by £623,470 in 2025, indicating genuine operational profitability, not just balance sheet manipulation.

  2. "Excellent immune system" — name shown to subscribers Debt Burden: With debt-to-equity at 8.2% and creditors falling due within one year at just £323K, the company is rarely vulnerable to creditor pressure.

  3. "Good muscle tone" — Asset Base Strength: Net assets of £3.94M with £1.96M in productive tangible assets (leasehold property, plant, machinery) show real operational substance.

  4. "Clean circulation" — Working Capital: The £2.4M working capital provides ample "blood flow" to fund day-to-day operations comfortably.

  5. "Mature patient" — 40 Years of Continuous Trading: Few companies survive four decades. This longevity signals durable business model, market adaptation, and resilience.

🟡 Symptoms Requiring Monitoring

  1. "Depleted cash reserves" — The £264K cash decline is the most concerning vital sign. While still healthy at £682K, the company is consuming cash faster than replenishing it from operations.

  2. "Swelling receivables" — Debtors doubled to £1.59M. This is the single largest "yellow flag": - Could indicate strong sales (positive) - Could indicate collection difficulties (negative) - Action required: Analyse debtor aging and days sales outstanding

  3. "Reduced inventory" — Stock fell 20% while debtors rose. This could indicate: - Faster inventory turnover (good) - Stock shortages from supply issues (bad) - Strategic reduction tied to lower demand

🔴 Items Worth a Closer Look

  1. The 2020 Anomaly: Total assets jumped from £1.48M (2019) to £7.36M (2020) — a near-fivefold increase. This suggests a major acquisition, asset injection, or business combination. Understanding this is key to interpreting recent trends.

  2. "Governance refresh" — Two director resignations in 2026 (name shown to subscribers, name shown to subscribers). May simply reflect normal board evolution, but warrants noting in governance review.

  3. Complex share structure: Multiple share classes (F, R, S, M, E, ED) suggest historical succession planning among a family-connected ownership group.

Historical Patient Chart — The Recovery Story

Net Assets Trajectory (£M) 2016: 0.67 → 2017: 0.72 → 2018: 0.60 → 2019: 0.72 ↓ Major event 2020 2020: 2.78 → 2021: 4.10 → 2022: 3.36 → 2023: 3.72 ↓ Post-event adjustment & debt reduction 2024: 3.32 → 2025: 3.94 📈 Recovery & Growth

The 2020-2021 surge followed by 2022 dip is a classic "consolidation period" pattern. Since 2022, the patient has steadily improved.


4️⃣ Recommendations — Prescriptions for Continued Wellness

💊 Immediate Actions (Within 30 days)

  1. Conduct a Debtor Audit: With debtors now at £1.59M (a £916K increase), implement a debtor aging analysis. Identify: - How much is over 60/90 days? - What's the credit control process? - Is bad debt provision appropriate?

  2. Cash Flow Reconciliation: Investigate the £264K cash reduction. Was it: - Used to fund the £303K tangible asset additions? - Locked up in debtors? - Spent on something else?

🏃 Short-term Actions (1-3 months)

  1. Strengthen Cash Reserves: Consider a working capital facility or improved collection cycle to rebuild cash buffer. Target: maintain cash above £1M for operational resilience.

  2. Director Succession Plan: With two recent resignations, formalise succession procedures and ensure continuity, especially given the family-connected ownership structure.

  3. Dividend Policy Review: With profits of £625K but only £1,100 in dividends, consider whether shareholders might benefit from modest distributions while maintaining reserves.

🛌 Long-term Wellness Plan (3-12 months)

  1. Scenario Planning: Given the 2020 anomaly and post-pandemic operating environment, model scenarios for: - Continued growth trajectory - Economic downturn resilience - Major capital investment opportunities

  2. Pension & Employee Retention: With 38 stable employees, ensure pension obligations and key-person risks are managed.

  3. Industry-Specific Risk Management: For medical device manufacturing: - Regulatory compliance (MHRA, CE marking, potential EU MDR) - Quality assurance certifications (ISO 13485) - Supply chain resilience for medical-grade materials

🩺 Annual Check-up Frequency

The patient should be reviewed annually at minimum, with quarterly "blood pressure checks" on cash and receivables given current trends.


📊 Final Assessment Summary

Category Grade Comments
Profitability A Consistent, strong profit generation
Liquidity A+ Industry-leading current ratio
Solvency A Minimal debt, strong equity base
Asset Quality B+ Receivables warrant monitoring
Cash Management B Trend declining — needs attention
Governance B+ Recent changes — watch for transition
Overall A- Financially very healthy

Names of the people mentioned are shown to subscribers. See subscription

Perspective: Financial Health Diagnostician · Model: minimax-m3 · Generated 16 October 2026